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AbstrAct
A case of drug-induced melanonychia due to cyclophosphamide is described in a patient with lupus nephritis. This 
resolved completely at 20 weeks after stopping the drug. Clinicians should be aware of the causes of melanonychia, 
and, if drug-induced melanonychia is suspected, the offending drug should be stopped whenever possible. 
Keywords: cyclophosphamide; melanonychia; adverse drug reaction.
Image In nephrology
cyclophosphamide-induced melanonychia
Mazhar H Amirali, Mogamat-Yazied Chothia
Division of Nephrology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
Received 15 January 2019; accepted 29 January 2019; published 07 February 2019.
Correspondence: Mazhar Amirali, mazheramirali@gmail.com.
© The Author(s) 2019. Published under a Creative Commons Attribution 4.0 International License.
A 62-year-old woman with systemic lupus erythematosus 
presented with new-onset hypertension and renal failure 
(serum creatinine 744 μmol/L), with an active urine sedi-
ment. A kidney biopsy revealed class IV lupus nephritis 
with >50% crescents. She was initiated on induction 
therapy using intravenous pulse methylprednisolone 
(1 g over 3 days) followed by oral cyclophosphamide and 
prednisone. The dose of cyclophosphamide was 75 mg 
daily for 2 months and subsequently 100 mg daily for 
7 months. Prednisone was initiated at a dose of 60 mg 
daily and tapered to 10 mg daily over the course of 
6 months. 
During routine follow-up at 9 months, she complained of 
the gradual onset of black discoloration of all her 
fingernails (Figure 1, panel A). Examination revealed sym-
metrical, almost homogeneous, grey-black discoloration 
of the nails that did not blanch with pressure. No other 
mucocutaneous areas were affected. The patient was 
otherwise clinically well.
Melanonychia is a rare and under-reported adverse effect 
of cyclophosphamide therapy [1]. Dermoscopy shows 
longitudinal thin grey lines on a homogeneous grey 
background [1]. Drug-induced melanonychia is thought 
to result from melanocyte activation with subsequent 
increased melanin synthesis and deposition [1], which is 
readily reversible after drug cessation. This form of 
melanonychia is not associated with any deleterious 
effects on health and there is no specific treatment. The 
differential diagnoses include melanoma, psoriasis, Addi-
son’s disease, phototherapy, electron beam therapy and 
exposure to various drugs [1,2]. 
In our patient, discontinuation of the cyclophosphamide 
resulted in complete resolution at 20 weeks of follow-up 
(Figure 1, panels B and C). Her lupus nephritis is in partial 
remission and she is currently receiving mycophenolate 
mofetil as maintenance therapy. 
Clinicians should review their patients’ prescriptions 
regularly, be aware of the various causes of melanonychia, 
and, if drug-induced melanonychia is suspected, the 
offending drug should be stopped whenever possible.
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Cyclophosphamide-induced melanonychia 
figure 1.  Melanonychia due to cyclophosphamide. panel a shows the prominent black discoloration of the nails (arrows) 
after 9 months of oral cyclophosphamide treatment. panels B and C illustrate resolution after stopping the drug at 9 and 20 weeks, 
respectively.
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